AstraZeneca to buy Alexion for $39B
Bio Pharma Dive
DECEMBER 12, 2020
The deal launches AstraZeneca, a company that has been growing mostly because of newer drugs for cancer and diabetes, into the market for rare disease treatments.
Bio Pharma Dive
DECEMBER 12, 2020
The deal launches AstraZeneca, a company that has been growing mostly because of newer drugs for cancer and diabetes, into the market for rare disease treatments.
World of DTC Marketing
DECEMBER 15, 2020
SUMMARY: Deloitte predicts that the percentage of virtual video visits to doctors will rise to 5% globally in 2021, up from an estimated 1% in 2019. While 5% may not sound like much, consider that 8.5 billion doctor’s visits, worth a total of approximately US$500 billion. The most time-consuming task is to make an appointment with your doctor just to ask for a new Rx or an Rx renewal.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
DECEMBER 14, 2020
The future of pharmaceutical manufacturing is mobile. Advances in cloud computing and the onset of Industry 4.0 has led to the proliferation of mobile IT solutions for manufacturing, including pharmaceuticals. Particularly, mobile workstations and tablets are becoming staples of the pharmaceutical manufacturing workflow due to their cost-effectiveness, particularly in demanding environments like cleanrooms, where even modular fixed human-machine interfaces (HMIs) can be exorbitantly priced and c
Camargo
DECEMBER 15, 2020
Whether a sponsor develops a new product or plans to license an exciting new asset developed somewhere else, commercial success or failure will depend on its understanding of the market and ability to develop an effective commercial strategy. The product may be based on an elegant and compelling scientific premise, but if it does not provide a set of benefits that could change current behaviors, or if it is not accessible to patients, it might be best to consider alternatives.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Bio Pharma Dive
DECEMBER 17, 2020
More active in neuroscience than most pharmaceutical firms, Novartis would gain three experimental drugs for depression, schizophrenia and movement disorders through the deal.
World of DTC Marketing
DECEMBER 17, 2020
SUMMARY: (Axios) The U.S. spent $3.8 trillion on health care last year, accounting for about 18% of the entire American economy, according to new federal data. The U.S. has by far the most expensive health care system in the world, and every year it eats up a little more — from the federal government, states, employers, and individuals. This is unsustainable.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
DECEMBER 17, 2020
A study in Nature Neuroscience shows SARS-CoV-2, the virus responsible for COVID-19, is capable of crossing the blood-brain barrier, likely contributing to symptoms of brain fog and other cognitive effects reported by people infected with the virus.
Bio Pharma Dive
DECEMBER 15, 2020
A review by agency staff affirmed the strongly positive results Moderna reported from a large Phase 3 study, clearing the way for a possible emergency authorization in the coming days.
World of DTC Marketing
DECEMBER 16, 2020
Pharma has adapted virtual ad boards which is essential for impact marketing. I’ve noticed, however, that some best practices for ad boards seem to be slipping. Here is a checklist. 1ne: “Let’s have an ad board.” The first question you need to ask is whether you really need an ad board. Ad boards should not be used to tell something you already know. 2wo : What’s our objective?
NY Times
DECEMBER 15, 2020
The positive review likely ensures that the F.D.A. will grant emergency authorization for a second coronavirus vaccine this week for millions of Americans.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
BioSpace
DECEMBER 15, 2020
After four people in the Pfizer-BioNTech's and three people in Moderna’s COVID-19 vaccine trials developed temporary facial weakness or paralysis, some people became concerned that it could happen to them. But experts suggest that the condition, known as Bell’s palsy, is fairly prevalent in the p.
Bio Pharma Dive
DECEMBER 17, 2020
Support from the advisory committee Thursday would likely result in an emergency authorization for the shot within days. Track the meeting's progress with BioPharma Dive's reporters here.
World of DTC Marketing
DECEMBER 18, 2020
SUMMARY: The “goodwill” that many believe was gained from the development of a Covid-19 may be more of a wish than a reality. Pharma companies are still too focused on profits while people continue to rely on prescription drugs to compensate for unhealthy lifestyles. The headline and byline in a Times editorial said it all “Don’t Fall for Big Pharma’s Savior Act, Heroic work went into the development of the coronavirus vaccines.
pharmaphorum
DECEMBER 17, 2020
Biology 2.0: Combining machine-learning, robotics and biology to deliver drug discovery of tomorrow. Intelligent OMICS, Arctoris and Medicines Discovery Catapult test in silico pipeline for identifying new molecules for cancer treatment. Medicines discovery innovators, Intelligent OMICS, supported by Arctoris and Medicines Discovery Catapult, are applying artificial intelligence to find new disease ‘drivers’ and candidate drugs for lung cancer.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioSpace
DECEMBER 13, 2020
Eureka Therapeutics' InvisiMask™ Human Antibody Nasal Spray can provide 10 hours of protection from SARS-CoV-2 virus in animal models, according to preclinical results released today. Now it’s heading to clinical trials.
Bio Pharma Dive
DECEMBER 16, 2020
Similar diabetes drugs from Novo have shown signs of promise in treating dementia. The Danish biotech is now putting that hypothesis to the test.
BioPharma Reporter
DECEMBER 17, 2020
New Zealand now has enough COVID-19 vaccines for everyone in the country, says the government, as it announces two new supply agreements with Novavax and AstraZeneca today.
Pharma Times
DECEMBER 15, 2020
The trial is expected to begin next month, with first data anticipated in the second quarter of 2020
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
BioSpace
DECEMBER 15, 2020
The U.S. Food and Drug Administration has authorized the first non-prescription, over-the-counter, at-home antigen test that can be used to identify infection with SARS-CoV-2, the virus responsible for COVID-19, in people two years of age or older.
Bio Pharma Dive
DECEMBER 18, 2020
The FDA's emergency authorization of the biotech’s shot bolsters an immunization campaign in the U.S. that’s just beginning.
BioPharma Reporter
DECEMBER 14, 2020
The US has started COVID-19 vaccinations this morning: after the Pfizer/BioNTech vaccine was granted Emergency Use Authorization (EUA) by the FDA on Friday.
NY Times
DECEMBER 15, 2020
The U.S., Britain, Canada and others are hedging their bets, reserving doses that far outnumber their populations, as many poorer nations struggle to secure enough.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
DECEMBER 16, 2020
The ABPI’s chief executive Dr Richard Torbett shares his views on how the industry has adapted to COVID-19 and explains why the post-pandemic future is looking bright for the UK industry. January 2020 would have been an interesting time for anyone to start a new job, but for Richard Torbett, who moved into the chief executive position at the ABPI after five years at the Association, it meant taking the helm of an organisation that quickly found itself on the frontline of global efforts to fight
Bio Pharma Dive
DECEMBER 14, 2020
A New York nurse was among the first to get the shot after FDA authorization late Friday. Many other health systems are either preparing to receive supplies or are already beginning immunizations.
BioPharma Reporter
DECEMBER 17, 2020
Valneva has started a Phase 1/2 trial of its COVID-19 vaccine: eying up potential regulatory approval in the fourth quarter of 2021. It champions a âtried and testedâ approach with its inactivated candidate.
BioSpace
DECEMBER 15, 2020
Novartis' Iptacopan isn’t the only drug to receive Breakthrough Therapy designation this week. Several other experimental treatments were also awarded the designation.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
NY Times
DECEMBER 17, 2020
Estados Unidos, el Reino Unido, Canadá y otros paÃses hicieron pedidos de vacunas que superan con creces a sus poblaciones, mientras muchas naciones pobres luchan por asegurarse las dosis que necesitan.
Bio Pharma Dive
DECEMBER 15, 2020
The acquisition marks a significant bet by Lilly on gene therapy's potential to address tough-to-treat neurological disorders like Parkinson's disease.
Pharma Times
DECEMBER 14, 2020
The triple combination therapy Trixeo Aerosphere cut the rate of moderate or severe exacerbations compared with dual-combination therapies in clinical trials
pharmaphorum
DECEMBER 14, 2020
The pharma industry has been making great strides forward in digital health, but one element of that – gamification – hasn’t yet made much headway in the sector. Armed with new data from a randomised clinical trial, one company is hoping to change that mindset. The company is FriendsLearn – based in India and with an R&D office in San Francisco – which recently reported results from a trial showing that its fooya!
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Let's personalize your content